From Closed Loop MedicineMay 16 2024 Closed Loop Medicine Ltd, a leading TechBio company developing combination prescription drug plus software therapy products that deliver personalized dose optimization, and Pharmanovia, a global pharmaceutical company that commercializes novel medicines and revitalizes, extends and expands the lifecycle of established medicines, today announced the initiation of their OptiZest study, ID: NCT06372470, and first patient recruitment.
Hypertension is a leading preventable cause of morbidity and premature death worldwide, impacting over 1 in 4 men and 1 in 5 women, and costing the NHS alone over £2.1 billion/year. Medication and lifestyle interventions have been shown to significantly reduce associated health risks and improve quality of life, however, poor drug tolerability and treatment-related side effects significantly impact adherence and overall disease management.
OptiZest is co-funded by both companies and led by Dr. Serge Engamba, GP and Clinical Research Lead at North Norfolk Primary Care. The study is also being supported by the National Institute for Health and Care Research.